ALNY Alnylam Pharmaceuticals, Inc.: חוב להון עצמי

Alnylam Pharmaceuticals (ALNY) generates steady cash from therapies for rare genetic pathologies that require lifelong medication. The current debt-to-equity ratio confirms the model's stability, with the value maintained at 0.78. Drug production flexibility is ensured through outsourced manufacturing, while a loyal staff of leading biochemists guarantees no talent shortage in research.

Selecting stocks with a high margin of safety begins with an analysis of the debt load. This indicator measures the ratio of total liabilities to equity, determining the risk of default or the efficiency of financial leverage. For Alnylam Pharmaceuticals (ALNY), this is critical for recovering R&D costs and implementing RNAi therapy. The current debt-to-equity ratio is 0.78. The trend of this metric reflects the business's resilience to cash flow gaps.